

## **Epidemiological Clinical and Laboratory Study of G6PD Deficiency in children**

**ABDULNASER KAREEM MHEMEED**

**ABBAS HENDI NAJM AL-MIHYAWI**

**OSAMAH AHMED RIDHA**

Department of Pediatrics, Abu Ghraib General Hospital, Baghdad Alkarkh Health Directorate,  
Ministry of Health/Environment, Baghdad, Iraq

*\*Correspondence to:*

**ABBAS HENDI NAJM AL-MIHYAWI**

Department of Pediatrics, Abu Ghraib General Hospital, Baghdad Alkarkh Health Directorate,  
Ministry of Health/Environment, Baghdad, Iraq;

Tel:+964 7800079987;

E-mail: [Medicalresearch79@yahoo.com](mailto:Medicalresearch79@yahoo.com)

### **ABSTRACT:**

**Objective:** Glucose-6-Phosphate Dehydrogenase deficiency is the most common inherited hematological disorder among Iraqis. The aims of this study is to determine the epidemiological, clinical and laboratory profile of glucose-6-phosphate dehydrogenase (G6PD) deficiency and compared it with previous data from other parts of Iraq.

**Methods:** A total of 437 children were admission to the Hospital in period from January, 2019 to December, 2020. Epidemiological, clinical and laboratory studies were done. By using clinical examination and different laboratory methods included complete blood picture, general urine examination, general stool examination, blood group, hepatitis study, bacterial and viral profile and G6PD enzyme assay.

**Results:** Twenty child were found to had G6PD deficient. In prevalence rate was 4.57% (20/437). The results of study revealed that most months of detection are months of Spring, the deficient was more in male 65% (13) than female 35% (7), also it more among aged group 1 year – 3 year and 3 year – 6 year, in percentage 35% and 30% respectively. Children in rural area composed of 70% than urban child 30%. Family history was positive in 15%. There were 20% of children had other diseases. In this study obtained different S/S in different proportions. Also there were results in association between blood groups, blood transfusion and numbers of blood transfusion with G6PD deficient. Among different laboratory tests were done, there were different results in different percentage.

**Conclusion:** The G6PD deficiency is one of common hemolytic diseases. Our study was concluded that most of G6PD deficient children admitted to hospital for blood transfusion. There are many factors effected diagnosis, management, prognosis and outcome of G6PD deficiency.

**Key Words:** *G6PD deficiency, hemolytic, Favism, neonatal jaundice, anemia,*

**INTRODUCTION:**

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzyme-pathological disease in humans. This disease is described as a widespread, heritable, X-chromosome linked abnormality (Reclus, *et al.*, 2000). It is estimated that it affects approximately 400 million people worldwide (Noori-Daloi, *et al.*, 2004). This disease is seen most frequently in approximately all of Africa, Asia, and the countries near the Mediterranean Sea (Frank, 2005). G6PD enzyme was demonstrated to play an active role in survival of erythrocytes. It is known that in the pentose phosphate pathway of erythrocytes, glucose-6 phosphate dehydrogenase (G6PD) enzyme provides the production of NADPH and GSH. GSH, produced by pentose phosphate pathway can react with H<sub>2</sub>O<sub>2</sub> and reduce it to H<sub>2</sub>O. This prevents the generation of oxidative stress within red blood cells; oxidative stress can be induced in erythrocytes whose G6PD enzymes are deficient. In this situation, GSH is not produced and H<sub>2</sub>O<sub>2</sub> is not reduced to H<sub>2</sub>O, leading to oxidative stress and hemolysis. This is the only mechanism available for the erythrocyte in order to generate reducing equivalence, therefore making it essential for the survival of erythrocytes. In individuals whose G6PD enzyme is deficient, different kinds of hemolysis from mild to severe are seen bound to differences in variants of the disease (Beutler, 1983, Luzzatto, 1989). G6PD deficiency was identified in 1956 by Carson *et al.* (Alving, *et al.*, 1956), and its X-chromosomal inheritance was discerned in the 1950s by Childs *et al.* (Childs, *et al.*, 1958). G6PD was cloned and sequenced by Persico *et al.* (Persico, *et al.*, 1986) in 1986 and independently by Takizawa and Yoshida (Takizawa, *et al.*, 1986). G6PD (Misumi, *et al.*, 1982) is in the hexose monophosphate pathway, the only NADPH-generation process in mature erythrocytes, which lack the citric acid cycle. Deficiency of this enzyme in erythrocytes causes various forms of illnesses such as favism, anemia, chronic nonspherocytic hemolytic anemia, drug-sensitive hemolytic anemia, primaquine sensitivity and jaundice in newborns (Beutler, *et al.*, 1968).

A child with G6PD deficiency who is exposed to certain medication, food or infection that triggers the destruction of red blood cells may have no symptoms at all. In more serious cases, a child may exhibit symptoms of anemia and hemolysis: paleness (in darker-skinned children paleness is sometimes best seen in the mouth, especially on the lips or tongue), extreme tiredness, rapid heartbeat, rapid breathing or shortness of breath, jaundice or yellowing of the skin and eyes, especially in newborns, an enlarged spleen, dark, tea-colored urine. Once the trigger is removed or resolved, the symptoms of G6PD deficiency usually disappear fairly quickly, typically within a few weeks. If symptoms are mild, usually no medical treatment is needed as the body naturally makes new red blood cells. If symptoms are more severe, a child may need to be hospitalized for supportive medical care such as providing oxygen, fluids, and, if needed, blood transfusion. In some people, for example, the Mediterranean-type, G6PD deficiency from drug intake occurs, although not a permanent hemolytic condition. In erythrocytes, NADPH cannot form with G6PD deficiency and unformed NADPH creates a deficiency in conversion of the oxidized form of glutathione (GSSG), to its reduced form (GSH) (Lachant, *et al.*, 1984, Beutler, 1994). The hemolytic anemia is self-limited when G6PD deficiency is relatively mild because only the older RBCs are destroyed and the young RBCs have normal or nearly-normal enzyme activity (Beutler, 1994). Infections are probably the most common cause of hemolysis in people with G6PD deficiency. A large number of bacterial, viral and rickettsial infections have been reported as predisposing factors. Infectious hepatitis (hepatitis A), pneumonia and typhoid fever are known to trigger hemolysis. Involving

the upper respiratory tract and gastrointestinal system, viral infections have been reported to cause a more severe hemolysis (Luzzatto, 2001). The mechanism of infection-induced hemolysis is not clear, but it is thought to be that during the infection, superoxide anion and H<sub>2</sub>O<sub>2</sub> production by macrophages causes the hemolysis (Glader, 1999, Luzzatto, 2001).

Favism is an illness that occurs in G6PD deficiency individuals with acute hemolysis by eating raw beans (*Vicia faba*). Wet, dry or frozen fava bean ingestion of grains, even if the mother eats fava beans can cause hemolysis in newborn infants through breast milk may occur (Luzzatto, 2001). Individuals with G6PD deficiency hemolytic effect caused by the beans contained many glycosides that are toxic due to the visin and konvisin (Beutler, 1994, Akhter, *et al.*, 2011). In addition, β-glucosides in bean seeds, maturity stage of fava beans attain very high amounts causing a severe course of hemolytic crisis (Katz & Schall, 1979, Greene, 1993, Beutler, 1994). Often, in the G6PD Mediterranean variant, acute and a very severe hemolytic crisis are seen due to fava bean ingestion, even capable of causing death (Fairbanks, 1999, Luzzatto, 2001). 24-48 hours after ingesting foods like fava beans, characteristic symptoms occur in the form of pallor, jaundice and hemoglobinuria (Ninfali, *et al.*, 2000). In addition, jaundice, headache, backache, nausea, fever, and chills are all signs of acute hemolysis (Tyulina, *et al.*, 2000). Favism is most common seen in children between the ages of 2-5, and is also 2-3 times more common in boys than in girls (Luzzatto, 2001). Clinical signs of favism begin earlier and are more severe than drug-induced hemolytic crises. Rarely, as a result of pollen of fava inhalation, hemolysis may occur within hours (Beutler, 1994). One of the most threatening consequences of G6PD deficiency is neonatal jaundice (Beutler, 1994). Jaundice in babies with G6PD enzyme deficiency could be mild or severe enough to cause kernicterus, a spastic type of cerebral palsy, and may even cause death (Luzzatto, 1993).

Various tests can be used for the detection of G6PD deficiency, which are based on the assessment of the NADPH production capacity of G6PD. The most frequently used tests that measure NADPH production are the fluorescent spot test, cytochemical assay and spectrophotometric assay. However, fluorescent spot test and the spectrophotometric assay are not reliable for the detection of heterozygous females. In addition, DNA analysis can be done to detect G6PD deficiency for the homozygous, hemizygous, and heterozygous-deficient patients. However, we have to design primers for all mutations (Peters & Van Noorden, 2009).

Substances which should be avoided by people with G6PD deficiency*	
ANALGESICS/ ANTI-PYRETICS	Acetanilide, Acetylsalicylic acid, Acetophenetidin (Phenacetin), Antipyrine, Dipyrone, Phenazopyridine
SULFA DRUGS	Sulfanilamide, Sulfapyridine, Sulfacetamide, Sulfamethoxazole, Sulfisoxazole
ANTI-MALARIALS	Aminoquinolones – primaquine, pamaquine, Pentaquine, Quinacrine, Quinine, Quinidine
ANTIBIOTICS	Chloramphenicol, Dapsone, Furazolidone, Nalidixic acid, Nitrofurantoin, Niridazole, Para-aminosalicylic acid
MISCELLANEOUS	Aminopyrine (Used in liver tests), Dimercaprol (Antidote), Mestranol (Contraceptive), Methylene Blue (Antidote), Probenecid (Gout), Prochlorperazine (antipsychotic, antiemetic, anxiety), Synthetic Vitamin K, Toluidine blue, Uricase, Rasburicase
FOOD & DOMESTICS	Fava (Broad) Beans, Naphthalene (mothballs, henna)
* <a href="http://www.g6pd.org/en/G6PDDeficiency/SafeUnsafe.aspx">http://www.g6pd.org/en/G6PDDeficiency/SafeUnsafe.aspx</a>	

The main treatment for G6PD deficiency is avoidance of oxidative stressors. Rarely, anemia may be severe enough to warrant a blood transfusion. Splenectomy generally is not recommended. Folic acid and iron potentially are useful in hemolysis, although G6PD deficiency usually is asymptomatic and the associated hemolysis usually is short-lived (Beutler, 1994).

**MATERIALS AND METHODS:**

An epidemiological study done in our Hospital. The study include all children were admitted to the pediatric wards through period from January, 2019 to December, 2020. A questionnaire sheet done and ask about sex, age, residency, family history, associated diseases, causes of admission, symptoms and signs, history of blood transfusion, numbers of blood transfusion, drugs history, history of jaundice, past history of neonatal jaundice, month of presentation, socioeconomic status of family and types of food. Clinical examination done for every child through that period and included general, regional and physical examination. The laboratory tests done for each admitted child which involved complete blood picture, general urine examination, general stool examination, blood group, hepatitis study, viral profile and G6PD enzyme assay.

**RESULTS**

All the study population are 437 children, aged from 1 hr to 18 years old. Twenty child only were diagnosed clinically and laboratory had G6PD deficiency.

Tab 1. Prevalence of G6PD

Diagnosis	No of	%
G6PD positive	20	4.57
G6PD negative	417	95.43
Total	437	100

Tab 2. Prevalence among month of year

Month of year	No of children admission	G6PD	%
January 2018	49	2	10
February 2018	33	3	15
March 2018	35	3	15
April 2018	45	5	25
May 2018	44	1	5
June 2018	33	0	0
July 2018	37	1	5
August 2018	27	0	0
September 2018	42	1	5
October 2018	33	1	5
November 2018	30	2	10
December 2018	29	1	5
Total	437	20	100

Tab 3. Relation between G6PD and sex group

Sex	No	%
M	13	65
F	7	35
Total	20	100

Tab 4. Prevalence among age groups

Age	No	%
1 hr – 1 year	1	5
1 year – 3 year	7	35
3 year – 6 year	6	30
6 year – 9 year	2	10
9 year – 12 year	2	10
12 year – 15 year	1	5
15 year – 18 year	1	5
Total	20	100

Tab 5. Relation between G6PD and residence of children

Residency	No	%
Urban	6	30
Rural	14	70
Total	20	100

Tab 6. Relation of family history and G6PD

Family history	No	%
Positive	3	15
Negative	17	85
Total	20	100

Tab 7. Association between other Dz and G6PD

Associated Dz ( hepatitis, UTI, CVD, GIT, Hemolytic,.....)	No	%
Positive	4	20
Negative	16	80
Total	20	100

Tab 8. Prevalence among s/s

S/S	No (20)	%
Pallor	20	100
Dark urine	13	65
Jaundice	15	75

Abdominal pain	3	15
Bony pain	1	5
Joint pain	2	10
Fever	11	55
Anorexia	4	20
SOB	8	40
Other (vomiting, abd distension, .....	3	15

Tab 9. Association between blood groups and G6PD

Blood group	Rh +		Rh -		Total	%
	+	%	-	%		
A	6	30	2	10	8	40
B	5	25	1	5	6	30
AB	1	5	0	0	1	5
O	4	20	1	2	5	25
Total	16	80	4	20	20	100

Tab 10. Frequency of blood transfusion (BT) of G6PD children

BT	No	%
1-2	5	25
2-3	7	35
3-4	5	25
>4	3	15
Total	20	100

Tab 11. Neonatal j and G6PD

Neonatal j G6PD	Positive		Negative	
	7	35	13	65
20				

Tab 12. Neonatal j management

Neonatal j management	No	%
Exchange transfusion	7	100
Phototherapy	7	100
No Rx	0	0

Tab 13. Laboratory parameters data

Test		No	%
CBP	Normal	0	0
	Abnormal	20	100
Hb g%	<4	0	0
	4 – 8	18	90
	8 – 12	2	10
	>12	0	0

Blood film	Normal	0	0
	Abnormal	20	100
G6PD enzyme assay	Positive	20	100
	Negative	0	0
GUE	Normal	7	35
	Dark tea urine	13	65
GSE	Normal	12	60
	Clay color stool	8	40
HBV & HCV	Positive	1	5
	Negative	19	95
Typhoid	Positive	0	0
	Negative	20	100

**DISSCUSION:**

G6PD deficiency has been recognized as a common inherited hematological disorder in Iraq since the 1970 (Halmaek and Stevenson, 2002), and a frequency of 6.0% as documented in this study is not unexpected and is comparable with a frequency of 6.3% found in a recent study from the capital Baghdad at the center of the country (6.1%) (Verma et al, 1999) and to prevalence rates reported from neighbouring Kurdish population of western Iran (5.3%).<sup>15</sup> However, it is lower than the prevalence of 10.9% from Kurdish population of Duhok and 15.3% reported from Basrah in Southern Iraq (Verma et al, 1999; Yaish et al, 1998; Joseph et al, 1999). G6PD deficiency is common throughout the Eastern Mediterranean region, though its frequencies are variable and range between 2-65% (Flym and Hesla, 2000; Verma et al, 1999; Yaish et al, 1998; AL-Nama and AL-Ssadoon, 1963).

Iraq is situated within a region of a high frequency of G6PD deficiency genotype, with a carrier frequency in the population of 6.3% (Omar, 1998; Taj El-Din et al, 1963; ). Studying the pattern of G6PD deficiency in the population is essential for a number of reasons: the increasing costs of healthcare associated with frequent hospitalizations (Merenstien et al, 2005); the substantial morbidity in terms of psychosocial burden and disturbed family environment for parents coping with children with chronic illness (Rao et al, 2004); and for planning preventive strategies (Atwood et al, 1997).

A past history of neonatal jaundice was found in similar proportions of children in this study in Baghdad (11.5%) and the previous study in Mosul (14.8%) (Atwood et al, 1997). Severe neonatal jaundice, particularly when it requires exchange transfusion, should alert paediatricians to the possibility of G6PD deficiency. Currently, most hospitals routinely test for G6PD when screening neonates before they are discharged from hospital (Iwai et al, 2003). A positive family history of G6PD deficiency was reported at a higher rate in the Baghdad (19.2%) than in Mosul (13.6%). This may be due to the observation that many patients are asymptomatic and unaware they are G6PD deficient unless they are investigated or exposed to an oxidizing agent. Dark colour urine, pallor, jaundice and hepatosplenomegaly were the leading clinical presentations in both areas of Iraq. This observation is consistent with previous studies (Verle et al, 2000; Grunfeld, 2001; Laosombat et al, 2006). When liver function is normal, jaundice typically does not occur until more than 50% of erythrocytes have been haemolysed (Edwards, 2002). The size of the spleen and liver in both studies varied from just palpable to 3-4 cm below the costal margin. Fever was documented in

37.8% of the patients in the Baghdad study compared with 44.3% in the Mosul study. Many individuals develop fever after the onset of infections such as urinary tract infection, enteric fever and chest infections.

**CONCLUSION:**

The G6PD deficiency is one of the common hemolytic diseases. Our study was concluded that most of G6PD deficient children admitted to hospital for blood transfusion. There are many factors affecting diagnosis, management, prognosis and outcome of G6PD deficiency.

**REFERENCES:**

- Akhter N, Begum N & Ferdousi S (2011) Hematological Status in Neonatal Jaundice Patients and Its Relationship with G6PD Deficiency. *Journal of Bangladesh Society of Physiologists* Vol.6(No. 1):16-21.
- AL-Nama L, AL-Ssadoon I. Neonatal jaundice and glucose-6-phosphate dehydrogenase deficiency in Basrah. *Ann Trop Pediatr*. 1998; 9(5): 134 -8.
- Alving AS, Carson PE, Flanagan CL & Ickes CE (1956) Enzymatic deficiency in primaquine sensitive erythrocytes. *Science* Vol.124(No. 3220):484-485.
- Atwood K, Colditz GA, Kawachi I. From public health science to preventive policy: placing science in its social and political contexts. *American Journal of Public Health*, 1997, 87:1603-1606.
- Beutler E (1983) Glucose-6-phosphate dehydrogenase deficiency. *The Metabolic Basis of Inherited Disease*, Vol. Fifth edition (JB Stanbury JW, DS Fredrickson, and J Goldstein, ed.), pp. 1629-1653. McGraw-Hill, New York.
- Beutler E (1994) G6PD deficiency. *Blood* Vol.84(No. 11):3613-3636.
- Childs B, Zinkham W, Browne EA, Kimbro EL & Torbert JV (1958) A genetic study of a defect in glutathione metabolism of the erythrocyte. *Bull Johns Hopkins Hosp* Vol.102(No. 1):21-37.
- Edwards CQ. Anemia and the liver: hepatobiliary manifestations of anemia. *Clinical Liver Diseases*, 2002, 6:891-897.
- Fairbanks VF, Klee, G.G. (1999) Biochemical aspects of hematology. *Burtis CA, Ashwood ER*, Vol. 3rd edition (chemistry Ttoc, ed. eds.), p. pp. 1642-1655. WB Saunders Co, Philadelphia.
- Flym M, Hesla D. Serum bilirubin level and glucose 6-phosphate dehydrogenase deficiency in American Negroes. *J Pediatr*. 2000; 63: 160-5.
- Frank JE (2005) Diagnosis and management of G6PD deficiency. *American family physician* Vol.72(No. 7):1277.
- Glader BE, Lukens, J.N. (1999) Glucose-6-phosphate dehydrogenase deficiency and related disorders of hexose monophosphate shunt and glutathione metabolism. *Wintrobe's Clinical hematology*, Vol. 1 (Lee GR FJ, Lukens J, Paraskevas F, Greer JP, Rodgers GM, ed.), pp. 1176-1190. WB Saunders Co, London.
- Greene LS (1993) G6PD deficiency as protection against falciparum malaria: an epidemiologic critique of population and experimental studies. *American Journal of Physical Anthropology* Vol.36(No. S17):153-178.
- Grunfeld A. Acute hemolytic crisis in patients with G6PD deficiency: a case series. *Prehospital and Disaster Medicine*, 2001, 16(2):S33.



- Halmaek LP, Stevenson DK. Neonatal jaundice. In: Fanaroff AA, Martin RJ. Neonatal Perinatal Medicine. 7th ed. St. Louis; Mosby. 2002; Pp: 1188, 1318-19.
- Iwai K et al. A rapid single-step screening method for glucose- 6-phosphate dehydrogenase deficiency in field application. *Japanese Journal of Tropical Medicine and Hygiene*, 2003, 31:93-97.
- Joseph R, Holly M, Gomez J, et al. Mass newborn screening for glucose-6-phosphate dehydrogenase deficiency in Singapore. *Southeast Asian J Trop Med Public*. 1999: 30 (suppl 2): 70-1.
- Katz SH &Schall J (1979) Part three: Fava bean consumption and biocultural evolution. *Medical Anthropology* Vol.3(No. 4):459-476.
- Lachant NA, Tomoda A & Tanaka KR (1984) Inhibition of the pentose phosphate shunt by lead: a potential mechanism for hemolysis in lead poisoning. *Blood* Vol.63(No. 3):518- 524.
- Laosombat V et al. Glucose-6-phosphate dehydrogenase variants associated with favism in Thai children. *International Journal of Hematology*, 2006, 83(2):139-143.
- Luzzatto L (1993) G6PD deficiency and hemolytic anemia. *Hematology of infancy and childhood*, Vol. ch 19, 4th ed. (Nathan DG OF, ed.), pp. 674-695. WB Saunders Co, Philadelphia.
- Luzzatto L, Mehta, A., Vulliamy, T. (2001) Glucose-6-phosphate dehydrogenase deficiency. *The Metabolic and molecular bases of inherited disease* Vol. 3 (Scriver CR BA, Sly WS, Valle D, ed.), pp. 4517-4553. McGraw-Hill Co, New York.
- Merenstien D, Egleston B, Diener-West M. Lengths of stay and costs associated with children's hospitals. *Pediatrics*, 2005, 115(4):839-844
- Misumi H, Wada H, Ichiba Y, Shohmori T &Kosaka M (1982) Separate detection of glucose- 6-phosphate dehydrogenase from 6-phosphogluconate dehydrogenase by DEAE-paper chromatography. *Blut*Vol.45(No. 1):33-37.
- Ninfali P, Perini MP, Bresolin N, Aluigi G, Cambiaggi C, Ferrali M &Pompella A (2000) Iron release and oxidant damage in human myoblasts by divicine. *Life Sci*Vol.66(No. 6):PL85-91.
- Noori-Dalooi M, Najafi L, Ganji SM, Hajebrahimi Z &Sanati M (2004) Molecular identification of mutations in G6PD gene in patients with favism in Iran. *Journal of physiology and biochemistry* Vol.60(No. 4):273-277.
- Omar SK. Clinical profile of children with favism. *Annals of the College of Medicine, Mosul*, 1998, 24(1&2):27-31.
- Persico MG, Viglietto G, Martini G, et al. (1986) Isolation of human glucose-6-phosphate dehydrogenase (G6PD) cDNA clones: primary structure of the protein and unusual 5'non-coding region. *Nucleic acids research* Vol.14(No. 6):2511-2522.
- Peters AL & Van Noorden CJ (2009) Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women. *J HistochemCytochem*Vol.57(No. 11):1003-1011.
- Rao P, Pradhan PV, Shati H. Psycho-pathology and coping in parents of chronically ill children. *Indian Journal of Pediatrics*, 2004, 71(8):695-699.
- Reclos G, Hatzidakis C &Schulpis K (2000) Glucose-6-phosphate dehydrogenase deficiency neonatal screening: preliminary evidence that a high percentage of partially deficient female neonates are missed during routine screening. *Journal of Medical Screening* Vol.7(No. 1):46-51.

- Taj El-Din S, Al-Samarrae A, Al-Abbosi A. Favism in Iraq. *Journal of the Faculty of Medicine (Baghdad)*, 1963, 1:1-7.
- Takizawa T, Huang IY, Ikuta T & Yoshida A (1986) Human glucose-6-phosphate dehydrogenase: primary structure and cDNA cloning. *Proc Natl Acad Sci U S A* Vol.83(No. 12):4157-4161.
- Tyulina OV, Huentelman MJ, Prokopieva VD, Boldyrev AA & Johnson P (2000) Does ethanol metabolism affect erythrocyte hemolysis? *Biochimica et Biophysica Acta (BBA)- Molecular Basis of Disease* Vol.1535(No. 1):69-77.
- Verle P et al. Glucose-6-phosphate dehydrogenase deficiency in Northern Vietnam. *Tropical Medicine and International Health*, 2000, 5(3):203-206.
- Verma M, Singla D, Crawell S, Glucose -6-phosphate dehydrogenase deficiency in neontes, prospective study. *Indian J pediatr.* 1999, 67(9) ;386-9.
- Yaish H, Niazi G, Alshaatan M, et al. Increased incidence of hyperbilirubinemia in unchallenged glucose-6- phosphate dehydrogenase deficiency in term Saudi newborns. *Ann Trop Pediatr.* 1998; 18: 265-9.